CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse aft...
Phase 1
Taipei, Taiwan and 6 other locations
pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 and spliceosome mutated Relapsed or Refractory Acute...
Phase 1
New Taipei City, Taiwan and 22 other locations
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and...
Phase 1
Taipei, Taiwan and 36 other locations
VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation...
Phase 3
Taipei, Taiwan and 250 other locations
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefi...
Phase 3
Taipei City, Taipei, Taiwan and 55 other locations
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible f...
Phase 3
Taipei, Taiwan and 172 other locations
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Phase 3
Taipei, Taiwan and 110 other locations
the dose-limiting toxicity (DLT) of study treatment in patients with Acute Myeloid Leukemia (AML) and Mantle Cell...
Phase 1
Taipei, Taiwan and 4 other locations
combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute...
Phase 3
Taipei, Taiwan and 288 other locations
available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second ...
Phase 3
Taipei, Taiwan and 72 other locations
Clinical trials
Research sites
Resources
Legal